Clinical trial NCT00125723 - References

Neutropenia — FIRST - Study of Pegfilgrastim Administered in the First and Subsequent Cycles of Myelosuppressive Chemotherapy

Citation(s)

•   Noga SJ, Choksi JK, Ding B, Dreiling L, Ozer H
  Low incidence of neutropenic events in patients with lymphoma receiving first-cycle pegfilgrastim with chemotherapy: results from a prospective community-based study. Clin Lymphoma Myeloma. 2007 May;7(6):413
•   Ozer H, Mirtsching B, Rader M, Luedke S, Noga SJ, Ding B, Dreiling L
  Neutropenic events in community practices reduced by first and subsequent cycle pegfilgrastim use. Oncologist. 2007 Apr;12(4):484-94.

A Multicenter, Open-label, Phase 4 Study of Pegfilgrastim Administered in the First and Subsequent Cycles of Myelosuppressive Chemotherapy

Details for clinical trial NCT00125723